Arena Pharmaceuticals (ARNA) Surges on VIVUS's (VVUS) Day
Tweet
Share
E-mail
Get Alerts ARNA Hot Sheet
Join SI Premium – FREE
Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) is surging higher Friday although no fundamental reason can be found to explain the action.
Rival VIVUS Inc. (Nasdaq: VVUS) is expected to receive FDA approval today, but this is for a erectile dysfunction drug avanafil and is not related to competing obesity drug Qnexa.
Shares of Arena Pharmaceuticals last traded at $2.74, up 27%.
Rival VIVUS Inc. (Nasdaq: VVUS) is expected to receive FDA approval today, but this is for a erectile dysfunction drug avanafil and is not related to competing obesity drug Qnexa.
Shares of Arena Pharmaceuticals last traded at $2.74, up 27%.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Scorpion Capital says short Twist Biosciences
- Musalem: strong growth and investment influencing bond market - CNBC
- Invesco cuts fees 20% amid redemption backlog in real estate fund - Bloomberg
Create E-mail Alert Related Categories
Momentum Movers, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
